The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis

Breast Cancer Research

Volumn 8, Issue 3, 2006, Pages

  Têtu, Bernard ^a   Brisson, Jacques ^b   Wang, Chang Shu ^a   Lapointe, Hélène ^a   Beaudry, Geneviève ^a   Blanchette, Caty ^b   Trudel, Dominique ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GELATINASE A; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; PROGESTERONE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UROKINASE; MATRIX METALLOPROTEINASE; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; STATISTICAL SIGNIFICANCE; STROMA CELL; SURVIVAL TIME; AGED; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; STROMAL CELLS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 33745157557     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1503     Document Type: Article

References (56)

1. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
2. Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995, 6:967-974.
3. Vihinen P, Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99:157-166.
4. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
5. Bigg HF, Morrison CJ, Butler GS, Bogoyevitch MA, Wang Z, Soloway PD, Overall CM: Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 2001, 61:3610-3618.
6. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA: Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990, 265:13933-13938.
7. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY: MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001, 263:209-223.
8. Lee KS, Rha SY, Kim SJ, Kim JH, Roh JK, Kim BS, Chung HC: Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clin Exp Metast 1996, 14:512-519.
9. Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ: Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 1998, 77:926-931.
10. Azzam HS, Arand G, Lippman ME, Thompson EW: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 1993, 85:1758-1764.
11. Tsunezuka Y, Kinoh H, Takino T, Watanabe Y, okada Y, Shinagawa A, Sato H, Seiki M: Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 1996, 56:5678-5683.
12. Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727.
13. Bachmeier BE, Iancu CM, Jochum M, Nerlich AG: Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach. Expert Rev Anticancer Ther 2005, 5:149-163.
14. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P: Stromelysin-3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993, 90:1843-1847.
15. Têtu B, Brisson J, Lapointe H, Bernard P: Prognostic significance of stromelysin 3, gelatinase A and urokinase expression in breast cancer. Hum Pathol 1998, 29:979-985.
16. Dressler LG, Bartow SA: DNA flow cytometry in solid tumors: practical aspects and clinical applications. Semin Diagn Pathol 1989, 6:55-82.
17. Erdos T, Best-Belpomme M, Bessada R: A rapid assay for binding estradiol to uterine receptor(s). Anal Biochem 1970, 37:244-252.
18. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:453-481.
19. Armitage P: Statistical Methods in Medical Research New York: John Wiley & Sons; 1991.
20. Têtu B, Brisson J, Côté C, Brisson S, Potvin D, Roberge N: Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993, 55:429-435.
21. Cox DR: Regression models and lifetables (with discussion). J R Statist Soc 1972, 34:187-220.
22. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001, 65:55-61.
23. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T: Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005, 89:215-220.
24. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM: Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998, 16:577-585.
25. Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, Davaris PS: MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 2003, 77:145-155.
26. Hsu MC, Chang HC, Hung WC: HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 2006, 281:4718-4725.
27. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997, 272:2446-2451.
28. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G: Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997, 250:751-757.
29. Pei D, Weiss SJ: Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996, 271:9135-9140.
30. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A: MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002, 16:555-564.
31. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY: Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer 2000, 86:15-23.
32. Mori M, Mimori K, Shiraishi T, Fujie T, Baba K, Kusumoto H, Haraguchi M, Ueo H, Akiyoshi T: Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 1997, 74:316-321.
33. Tsunezuka Y, Kinoh H, Takino T, Watanabe Y, Okada Y, Shinagawa A, Sato H, Seiki M: Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 1996, 56:5678-5683.
34. Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P, Foidart JM: High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 1996, 65:209-213.
35. Mimori K, Ueo H, Shirasaka C, Mori M: Clinical significance of MT1-MMP mRNA expression in breast cancer. Oncol Rep 2001, 8:401-403.
36. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, Okada Y: Expression and tissue localization of membrane-types 1,2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997, 57:2055-2060.
37. Polette M, Gilles C, Marchand V, Seiki M, Tournier JM, Birembaut P: Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells. Clin Exp Metastasis 1997, 15:157-163.
38. Bisson C, Blacher S, Polette M, Blanc JF, Kebers F, Desreux J, Tetu B, Rosenbaum J, Foidart JM, Birembaut P, Noel A: Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer 2003, 105:7-13.
39. Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M: Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 2000, 24:334-340.
40. Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999, 189:161-168.
41. Ishigaki S, Toi M, Ueno T, Matsumoto H, Muta M, Koike M, Seiki M: Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res 1999, 90:516-522.
42. Strongin AY, Collier I, Bannikiv G, Marmer BL, Grants GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270:5331-5338.
43. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P: Membrane-type matrix metalloproteinase (MTMMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinomas. Proc Natl Acad Sci USA 1995, 92:2730-2734.
44. Gorogh T, Beier UH, Baumken J, Meyer JE, Hoffmann M, Gottschlich S, Maune S: Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck 2006, 28:31-39.
45. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S: Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002, 97:425-431.
46. Visscher DW, Hoyhtya H, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Friedman R: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994, 59:339-344.
47. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T: Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma - tissue immunoreactivity predicts aggressive clinical course. Mod Pathol 2006, 19:208-217.
48. Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y: Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004, 10:634-640.
49. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr, Kallakury BV: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003, 16:198-205.
50. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A: Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994, 107:2373-2379.
51. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A: TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998, 75:246-253.
52. Saad S, Bendall LJ, James A, Gottlieb DJ, Bradstock KF: Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Res Treat 2000, 63:105-115.
53. Noel AC, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle JM, Remacle AG, Kevers F, Brown P, Calberg-Bacq CM, Foidart JM: Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998, 76:267-273.
54. Gohji K, Fujimoto N, Fujii A, Komiyama T, Okawa J, Nakajima M: Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 1996, 56:3196-3198.
55. Nuovo GL, MacConnell PB, Simsir A, Valea F, French DL: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995, 55:267-275.
56. Onisto M, Riccio MP, Scannapieco P, Caenazzo C, Griggio L, Spina M, Stetler-Stevenson WG, Garbisa S: Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. Int J Cancer 1995, 63:621-626.